my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
03-02-2012: Athersys, Inc. announced grant funding aggregating $3.6 million to further advance its MultiStem® product programs and cell therapy platform. Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke (NINDS) to develop MultiStem for the treatment of traumatic brain injury (TBI). In addition, Athersys’ subsidiary based in Belgium, ReGenesys BVBA, was awarded a $1.2 million (€0.9 million) grant from the Belgium’s Agency for Innovation by Science and Technology (IWT) to further develop cell therapy formulations and manufacturing capabilities. The company has also been awarded funding recently to work in other areas, such as using MultiStem to treat chronic cardiovascular disease.
“These grant awards provide us with additional funding to support further development of MultiStem in specific therapeutic areas, as well as enhance our manufacturing platform,” said Dr. Gil Van Bokkelen, Athersys Chairman & CEO. “Historically, we have been very successful at obtaining this type of funding, which reflects our commitment to outstanding science and technology development, and development of innovative new therapies.”
The work under the NINDS grant to develop MultiStem for the treatment of TBI will be conducted in collaboration with researchers at The University of Texas Health Science Center at Houston (UTHealth) Medical School. The research program will include preclinical safety and efficacy studies required to support an Investigational New Drug (IND) application and the clinical investigation of MultiStem treatment of TBI.
The IWT grant will fund a product and process development program undertaken in Belgium by ReGenesys, Athersys’ affiliate. A principal focus of these efforts will be the continued development of serum-free formulations for the manufacture of MultiStem and related cell therapy products. ReGenesys researchers will collaborate with researchers from the Katholieke Universiteit of Leuven, as well as certain corporate partners to complete the program.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Athersys Awarded $3.6 Million in Grant Funding For Stem Cell Product Development
Athersys, Inc. announced grant funding aggregating $3.6 million to further advance its MultiStem® product programs and cell therapy platform. Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke ( ... more
Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced updated results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. T ... more
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. more
Shedding new light on infant brain development
A new study by Columbia Engineering researchers finds that the infant brain does not control its blood flow in the same way as the adult brain. The paper, which the scientists say could change the way researchers study brain development in infants and children, is published in Proceedings o ... more
Athersys Awarded $3.6 Million in Grant Funding For Stem Cell Product Development
Athersys, Inc. announced grant funding aggregating $3.6 million to further advance its MultiStem® product programs and cell therapy platform. Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke ( ... more
Gene scan finds link across array of childhood brain disorders
Mutations in a single gene can cause several types of developmental brain abnormalities that experts have traditionally considered different disorders. With support from the National Institutes of Health, researchers found those mutations through whole exome sequencing. "This is going to c ... more
National Institute of Neurological Disorders and Stroke (NINDS)
NINDS ) is the nation's leading funder of research on the brain and nervous system. The NINDS mission is to reduce the burden of neurological disease – a burden borne by every age group, by every segment of society, by people all over the world. more
Multiplicom receives €200,000 grant for novel non-invasive pre-natal test
Multiplicom, a molecular diagnostics company specializing in the design, development, production and commercialization of molecular genetic tests based on massively parallel sequencing, announced that it has been awarded a €200,000 grant from the Flemish agency for Innovation by Science and ... more
Athersys Awarded $3.6 Million in Grant Funding For Stem Cell Product Development
Athersys, Inc. announced grant funding aggregating $3.6 million to further advance its MultiStem® product programs and cell therapy platform. Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke ( ... more
IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012
reMYND NV announced that it has received a grant of 1.48 million EUR from IWT, the Flemish agency for Innovation by Science and Technology, to accelerate its Diabetes program. reMYND’s Drug Discovery & Development focuses on the development of disease-modifying drugs for patients suffering ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
